Skip to content 
AMM 337: Aliaxin Fillers: Safety in Aesthetic Medicine Confirmed
January 26, 2025
This episode dives into the safety profile of Aliaxin fillers, a hyaluronic acid filler made by IBSA Farmaceutici Italia. Using data collected globally from 2018 to 2023, the study examines the prevalence of adverse events and confirms that Aliaxin fillers maintain a solid safety record, with manageable issues like oedema and swelling. Featuring insights from experts such as Dr. Hema Sundaram and Dr. Beatriz Molina, the episode highlights the importance of ongoing surveillance for ensuring safe aesthetic practices.
Quick Takes
- Recent study evaluated extensive post-marketing data of Aliaxin fillers
- No significant escalation in adverse events reported
- Aliaxin fillers maintain a strong safety record with manageable common issues
Episode Transcript
Today is January 26th, 2025, and we’re looking into the safety profile of Aliaxin fillers, a type of hyaluronic acid filler produced by IBSA Farmaceutici Italia. A recent study evaluated extensive post-marketing data collected between 2018 and 2023 to ensure these fillers maintain a strong safety record.
The research, involving experts like Dr. Hema Sundaram from the University of Manchester and Dr. Beatriz Molina of Medikas Clinic, analyzed reports globally gathered from healthcare professionals and consumers. They found no significant escalation in adverse events during this period, reinforcing these fillers’ reputation for safety. Common issues included oedema and swelling, but these remained within a manageable scope.
This study underscores the importance of continuous surveillance to ensure safe aesthetic practices. So, it seems Aliaxin fillers are still holding strong as a reliable choice for aesthetic procedures. Thanks for tuning in, and keep looking forward to more safe and beautiful enhancements in the world of aesthetic medicine!
